Management discusses the KOMET-007 combination trial of the Company’s oral and selective menin inhibitor, ziftomenib, on a conference call to be held on December 9 at 8 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology management to meet with Cantor Fitzgerald
- BofA lowers Kura Oncology price target to $29, sees buying opportunity
- Nvidia reports Q3 beat, Starbucks explores China partnerships: Morning Buzz
- Kura Oncology price target lowered to $18 from $22 at Scotiabank
- Kura Oncology price target lowered to $34 from $37 at Wedbush